An investigational drug studied in animals significantly reduced damage to heart muscle from a heart attack and minimized the risk of bleeding during follow-up treatments, according to a study by scientists at the School of Medicine. Pictured is senior author Dana Abendschein, PhD.
A simple cut to the skin unleashes a complex cascade of chemistry to stem the flow of blood. Now, scientists at Washington University School of Medicine in St. Louis have used evolutionary clues to reveal how a key clotting protein self-assembles. The finding sheds new light on common bleeding disorders.
A five-year, $3.7 million clinical trial will investigate how to balance the benefits and risks of warfarin, a drug that helps prevent potentially deadly blood clots. The multicenter study, led by researchers at Washington University School of Medicine in St. Louis, will evaluate customized warfarin dosage based on patient genetics and will test which range of blood clotting is optimal in orthopedic patients.